Anti-Neoplastics Flashcards
cell cycle nonspecific alkylating agents
mechlorethamine, carmustine
cell cycle specific phase nonspecific alkylating agents
cyclophosphamide
least selective of the anti-neoplastics
alkylating agents
typical side effects of anti-neoplastics
myelosuppression, GI effects (nausea/vomiting), alopecia
nitrogen mustards
mechlorethamine, cyclophosphamide
nitrosoureas
carmustine
non-Hodgkins lymphoma drug
mechlorethamine
cyclophosphamide: mechanism, cell cycle specificity, side effects, uses
prodrug activated by liver cytochrome P450s, cell cycle specific phase nonspecific, bladder toxicity, broad uses
carmustine: cell cycle specificity, uses
cycle-nonspecific, brain tumors (crosses blood-brain barrier)
treats brain tumors
carmustine
methotrexate: mechanism
binds to dihydrofolate reductase and prevents formation of tetrahydrofolate
followed by “rescue” of host cells by leucovorin
methotrexate
methotrexate: side effects and uses
myelosuppression, GI damage, renal tubular necrosis, displaces other drugs from serum albumin; acute lymphocytic leukemia (ALL)
pyrimidine analogs
5-FU, cytarabine
5-FU: mechanism, uses
pyrimidine analog that inhibits RNA and DNA synthesis; broad spectrum of uses but mostly for GI cancers
cytarabine: mechanism, side effects, uses
pyrimidine analog that causes chain termination of DNA, myelosuppression and neurotoxicity, acute myelocytic leukemia (AML)
has neurotoxicity and myelosuppression as side effects
cytarabine
pyrimidine analog that causes chain termination of DNA
cytarabine
treats acute myelocytic leukemia (AML)
cytarabine, 6-MP, etoposide
6-mercaptopurine: mechanism, metabolism, use
purine analog, inhibits RNA and DNA synthesis; metabolized by TPMT; acute leukemias
patients with no functional TPMT cannot tolerate what drug?
6-mercaptopurine
hydroxyurea: mechanism
inhibits ribonucleotide reductase, prevents DNA synthesis, arrests cells at G1-S interface
hydroxyurea: use
granulocytic leukemia
inhibits ribonucleotide reductase
hydroxyurea
treats granulocytic anemia
hydroxyurea
binds to tubulin, inhibiting proper formation of microtubules and mitotic spindle
vincristine, vinblastine
major differences between vincristine and vinblastine
vinblastine is strongly myelosuppressive and treats breast cancer, vincristine treats acute lymphocytic leukemia (ALL)
vinca alkaloids: mechanism
binds to tubulin, inhibiting proper formation of microtubules and mitotic spindle
enhances assembly and stability of microtubules
taxanes (paclitaxel)
paclitaxel mechanism
enhances assembly and stability of microtubules, interferes with DNA repair
paclitaxel: use, side effect
refractory ovarian cancer; peripheral neuropathy
treats refractory ovarian cancer
paclitaxel
antitumor antibiotic
doxorubicin
only drug with some anti-angiogenic properties
doxorubicin
doxorubicin: cell cycle specificity
cycle-specific phase non-specific
multi-faceted mechanism of doxorubicin
- intercalates in DNA, distorting DNA helix 2. causes lipid peroxidation and free radical generation 3. binds to DNA + topoisomerase II
doxorubicin: unique side effect
cardiomyopathy (cardiotoxicity)
cardiomyopathy (cardiotoxicity) as a side effect
doxorubicin
pulmonary toxicity as a side effect
bleomycin
bleomycin: mechanism
iron-containing glycopeptides that bind to DNA, makes site-specific DNA breaks, phase-specific for G2
bleomycin: unique side effect
pulmonary toxicity
etoposide: mechanism
stabilizes DNA-topoisomerase II complexes, results in dsDNA breaks that cannot be repaired
goal is to limit chemotherapy-induced neutropenia
filgrastim (G-CSF)
filgrastim (G-CSF): unique side effect
bone pain
filgrastim (G-CSF): mechanism
promotes progenitor of neutrophils
treats breast cancers that overexpress HER2
trastuzumab
trastuzumab: mechanism
monoclonal antibody that binds HER2 receptor and blocks proliferation of cells
has nephrotoxicity as a side effect
cisplatin
cisplatin: mechanism; cycle specificity
platinum coordination complex, causes DNA crosslinks; cycle-specific phase-nonspecific
cisplatin: unique side effect
nephrotoxicity
revolutionized treatment of testicular cancer
cisplatin
procarbazine: mechanism
activated in vivo by liver enzymes to methylating agent which causes chromosomal damage
procarbazine: use
Hodgkin’s lymphoma
treats Hodgkin’s lymphoma
procarbazine
prednisone: mechanism
binds to steroid receptors, depress expression of many growth related genes, induce nucleases which may modulate cell lysis
prednisone: uses, palliative effects
lymphoma, leukemia, breast cancer; anti-emetic, anti-inflammatory, stimulates appetite
estrogen receptor antagonist
tamoxifen
tamoxifen: mechanism, uses
estrogen receptor antagonist that competitively blocks estrogen receptors in breast tissue, cytostatic (stops cell growth without killing the cells); pre-menopausal metastatic breast cancer and advanced post-menopausal breast cancer, breast cancer prophylaxis for those at higher risk
breast cancer prophylaxis for those at higher risk
tamoxifen
tamoxifen: metabolism
activated by CYP2D6
tamoxifen: unique side effects
bone and other musculoskeletal pain, may increase rates of uterine/endometrial cancer
may increase rates of uterine/endometrial cancer
tamoxifen
blocks conversion of angdrogens to estrogens by inhibiting aromatase
letrozole
letrozole: mechanism, use
blocks conversion of angdrogens to estrogens by inhibiting aromatase; first line treatment of post-menopausal advanced or metastatic breast cancer
analog of GnRH
leuprolide
leuprolide: mechanism, use, side effects
analog of GnRH, desensitizes GnRH signaling and decreases testosterone; advanced hormonally responsive prostate cancer; hot flashes and impotence
treats advanced hormonally responsive prostate cancer
leuprolide
has side effects of hot flashes and impotence
leuprolide
antiandrogen that blocks androgen receptors
flutamide
flutamide: mechanism and use
antiandrogen that blocks androgen receptors; metastatic prostate cancer
3 drugs that lack significant bone marrow toxicity
vincristine, prednisone, bleomycin
treats metastatic prostate cancer
flutamide
define concurrent inhibition
inhibitors block two separate pathways that lead to the same end product
define complementary inhibition
one drug affects the function of an end product, the other drug affects the synthesis of that end product
define the synchronization strategy of antineoplastic therapy
synchronize cells so they are in one phase and then use a drug that is specific for that phase
define the recruitment strategy of antineoplastic therapy
bring cells out of G0 and back into cell cycle via therapy with cell cycle-nonspecific drugs and then hit them with cycle-specific drugs
which drug has bladder toxicity (cystitis) as a side effect and what drug prevents this?
cyclophosphamide; mesna
inhibits BCR-ABL tyrosine kinase in CML
imatinib mesylate (Gleevec)
imatinib mesylate (Gleevec): mechanism, net effect
inhibits BCR-ABL tyrosine kinase in CML, net effect blocks cell proliferation and increases apoptosis